DiscoveryProbe™ FDA-approved Drug Library: Enabling Next-Generation Cellular Screening and Drug Repurposing

Introduction

As the landscape of drug discovery evolves, the integration of clinically validated compounds into high-throughput and high-content screening platforms is accelerating translational breakthroughs. The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) emerges as a transformative resource, comprising 2,320 bioactive compounds approved by regulatory agencies such as the FDA, EMA, HMA, CFDA, and PMDA. Unlike prior articles that focus on workflow optimization or select disease contexts, this review provides a rigorous, mechanistic perspective on how the DiscoveryProbe™ library is uniquely enabling next-generation cellular assays and drug repurposing strategies—especially in the context of viral protease inhibition and intracellular target validation.

Mechanism of Action and Composition of the DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library offers unparalleled chemical and biological diversity, encompassing receptor agonists and antagonists, enzyme inhibitors, ion channel modulators, and signal pathway regulators. Representative compounds—such as doxorubicin, metformin, and atorvastatin—reflect the library’s coverage of approved drugs with well-characterized mechanisms. Each compound is supplied as a pre-dissolved 10 mM DMSO solution, stable for up to 24 months at –80°C, and formatted for integration into 96-well microplates, deep well plates, or 2D barcoded screw-top storage tubes. This optimizes the library for high-throughput screening (HTS) and high-content screening (HCS), facilitating rapid, reproducible assay deployment across multiple research domains.

Cell-Based Screening: A Paradigm Shift in Drug Repurposing and Target Identification

While traditional biochemical and in silico approaches have long dominated early-stage drug discovery, their limitations—such as poor translation to intact cellular environments—are increasingly evident. Cell-based assays, powered by libraries like DiscoveryProbe™, address these gaps by:

• Validating compound permeability, stability, and bioactivity in physiologically relevant contexts.
• Enabling the identification of hits that require specific intracellular conditions or co-factors.
• Providing a platform for phenotypic screening, which is especially valuable for drug repositioning screening and pharmacological target identification.

This approach is exemplified by the recent work of Sigurdardóttir et al. (2024), who developed a genetically engineered yeast platform to screen approximately 2,500 small molecules—including FDA-approved drugs—for inhibition of the SARS-CoV-2 main protease (MPro). Their cell-based positive selection system revealed inhibitors—including boron-containing proteasome inhibitors—that had previously eluded detection in standard enzymatic assays, underscoring the unique value of cellular screening platforms enabled by comprehensive libraries like DiscoveryProbe™.

Comparative Analysis: DiscoveryProbe™ Versus Traditional and In Silico Screening

Previous articles, such as 'DiscoveryProbe FDA-approved Drug Library: Accelerating High-Throughput Screening', highlight the efficiency gains in screening workflows. However, this article delves deeper, contrasting the cellular screening paradigm with conventional in vitro and in silico methods:

• Biochemical Assays: While these offer target specificity, they often miss compounds whose activity is context-dependent or reliant on cellular milieu.
• In Silico Screening: Computational docking provides rapid hypothesis generation but suffers from a high rate of false positives and poor translation to living systems.
• Cell-Based Assays (DiscoveryProbe™-enabled): Capture real-world bioactivity, membrane permeability, and intracellular stability—crucial for identifying clinically viable candidates and repositioning existing drugs.

Sigurdardóttir et al. (2024) demonstrated that boron-containing proteasome inhibitors—such as bortezomib, delanzomib, and ixazomib—were only identified as effective MPro inhibitors when screened in a yeast cellular system, not in standard biochemical assays. This is attributable to the compounds’ requirement for non-standard intracellular conditions, which are faithfully recapitulated in cell-based models. Thus, the DiscoveryProbe™ FDA-approved Drug Library uniquely empowers researchers to uncover such context-dependent activities, especially in signal pathway regulation and enzyme inhibitor screening.

Advanced Applications in Antiviral and Mechanistic Research

Antiviral Drug Discovery and Emerging Pathogens

The COVID-19 pandemic has underscored the urgent need for rapid and flexible antiviral drug discovery platforms. Cellular screening with the DiscoveryProbe™ library enables:

• Rapid identification of antiviral candidates: By leveraging approved drugs, researchers can bypass lengthy safety evaluations and focus on efficacy in cellular or viral infection models.
• Targeting viral proteases and non-canonical pathways: As demonstrated by Sigurdardóttir et al. (2024), cell-based screens can detect inhibitors that are missed by conventional in vitro enzymatic assays due to buffer or cofactor requirements. Their yeast system, adaptable to other viral proteases, provides a model for screening large, diverse compound libraries like DiscoveryProbe™.
• Facilitating drug repositioning screening: Since all compounds in the library are clinically approved, hits can be rapidly advanced into preclinical or clinical studies for new indications.

This approach builds upon, but is distinct from, prior analyses such as 'Transforming Covalent Inhibitor Discovery', which examined covalent inhibitor discovery in a broad sense. Here, we specifically highlight the nuanced interplay between compound chemistry, intracellular environment, and screening methodology—elements that are pivotal for antiviral and emerging infectious disease research.

Mechanistic Studies in Cancer and Neurodegenerative Disease

While mechanistic and translational studies in oncology and neurodegeneration have been explored in articles like 'Enabling Precision Neurodegenerative Disease Research', this article advances the discussion by focusing on how cell-based, high-content screening can unravel context-dependent drug mechanisms and off-target effects:

• Cancer Research Drug Screening: The library’s coverage of diverse mechanisms supports phenotypic screens for apoptosis, cell cycle modulation, and pathway-specific responses. This is particularly impactful when used in live-cell imaging or multiplexed reporter assays.
• Neurodegenerative Disease Drug Discovery: Cell-based HTS and HCS platforms can assess neuroprotection, synaptic modulation, and pathway regulation in relevant cell types, accelerating therapeutic hypothesis generation and validation.
• Signal Pathway Regulation: The inclusion of compounds targeting kinases, phosphatases, GPCRs, and ion channels enables dissection of complex signaling networks under physiologically relevant conditions.

Technical Features Supporting Cutting-Edge Screening

The DiscoveryProbe™ library’s formulation as pre-dissolved DMSO solutions at defined concentrations ensures assay consistency and compatibility with automation. Its flexible storage formats—96-well microplates, deep well plates, and 2D barcoded tubes—are optimized for high-throughput robotics and data traceability in both academic and industrial settings. Furthermore, compound stability at –20°C (12 months) or –80°C (24 months) supports long-term, multi-stage projects, while shipping protocols (on blue ice for evaluation samples, room temperature or blue ice for other sizes) accommodate various research requirements.

Integrating DiscoveryProbe™ into Custom Cellular Assays: Practical Considerations

Researchers aiming to maximize the impact of DiscoveryProbe™ in cellular screening should consider:

• Assay design: Leverage reporter-based systems (e.g., FlipGFP for protease activity) or phenotypic endpoints (e.g., viability, differentiation, pathway activation).
• Buffer and media optimization: As highlighted by Sigurdardóttir et al. (2024), non-standard conditions may be required to reveal specific compound activities.
• Multiplexed readouts: High-content imaging and omics integration can provide mechanistic insights and facilitate hit triage.
• Comparative profiling: Combine DiscoveryProbe™-enabled screens with genetic perturbation or CRISPR libraries for synergistic discovery.

Conclusion and Future Outlook

The DiscoveryProbe™ FDA-approved Drug Library has ushered in a new era of cellular screening and drug repositioning, enabling researchers to move beyond traditional, reductionist assays. By providing a comprehensive, ready-to-screen set of clinically validated compounds, it empowers the discovery of novel mechanisms, context-dependent activities, and translational candidates for a broad range of biomedical challenges. Future directions include integrating DiscoveryProbe™ with AI-driven phenotypic analytics, expanding to new disease models, and adapting screening protocols to emerging threats, as exemplified by recent advances in antiviral research (Sigurdardóttir et al., 2024).

This article has focused on the unique value of cell-based screening and mechanistic validation, building on—but distinct from—prior reviews such as workflow-centric analyses and disease-specific deep-dives. By integrating technical rigor, practical guidance, and insights from the latest scientific literature, the DiscoveryProbe™ library stands as a cornerstone for next-generation biomedical research.